Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283694 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05283694 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 48 participants.
The verdict
NCT05283694, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
Interventions
- DRUG risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05283694
The ClinicalTrials.gov registry entry for NCT05283694 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risankizumab is the first listed.
NCT05283694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05283694 about?
NCT05283694 is a clinical study titled "A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants". The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
What is the current status of trial NCT05283694?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2017-09-11. Estimated completion is 2018-06-12.
What interventions are being tested in trial NCT05283694?
The interventions under investigation include: risankizumab (DRUG).
Who is sponsoring clinical trial NCT05283694?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.